Clinical trial
Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large…
NCT00169143 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00169143 |
|---|---|
| Title | Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma |
| Official title | Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-adjusted Ipi >or= 2) |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Untreated CD20-positive Large B-cell Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | Rituximab + ACVBP regimen plus Pegfilgrastim, Autologous stem cell transplant |
| Enrollment | 60 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 23, 2018 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: